167 related articles for article (PubMed ID: 35909273)
1. Cancer Immunotherapy: Diverse Approaches and Obstacles.
Sanatkar SA; Heidari A; Rezaei N
Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
3. Signaling new therapeutic opportunities: cytokines in prostate cancer.
Chandran E; Meininger L; Karzai F; Madan RA
Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL; Basu S; Soni V; Jaiswal RK
Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
[TBL] [Abstract][Full Text] [Related]
5. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
7. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
10. Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.
Sheikhi A; Jafarzadeh A; Kokhaei P; Hojjat-Farsangi M
Iran J Immunol; 2016 Sep; 13(3):148-66. PubMed ID: 27671507
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
12. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune evasion: insights from CRISPR screens and future directions.
Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
15. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns.
Yamamoto T; Kimura T; Ueta E; Tatemoto Y; Osaki T
Oncology; 2003; 64(4):407-15. PubMed ID: 12759539
[TBL] [Abstract][Full Text] [Related]
16. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
[TBL] [Abstract][Full Text] [Related]
17. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
18. Improving Cancer Immunotherapy with CRISPR-Based Technology.
Li Z; Fei T
Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
[TBL] [Abstract][Full Text] [Related]
19. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
20. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]